International COVID-19 Blood Cancer Coalition (ICBCC)

PATIENT IMPACT STATEMENT AND RECOMMENDATIONS
Protecting immunocompromised blood cancer patients during the COVID-19 pandemic

Date of release: 21 February 2022 / last updated: 26 February 2022

A multi-stakeholder coalition consisting of representatives from the global patient advocacy and clinical community has formed the International COVID-19 Blood Cancer Coalition (ICBCC) to address the specific impact of the pandemic on immunocompromised blood cancer patients (both acute and chronic), like those living with Chronic Lymphocytic Leukemia (CLL), and to recommend solutions and actions to mitigate those risks.

The Problem

The estimated share of those who are immunocompromised or immunosuppressed (IC/IS) is between two and three percent of the total global population. All are more vulnerable to contracting and suffering poor outcomes with COVID-19. Sadly, during the last two years their circumstances have been neglected to a larger or smaller extent with marked differences across geographical locations, leaving some to call them the "Prisoners of the Pandemic".

Their antibody responses to COVID-19 vaccines and even boosters have been repeatedly proven to be less predictable and robust when compared to the general population\(^i\),\(^ii\),\(^iii\). However, there is also evidence that boosters do yield benefits for people living with hematologic malignancies\(^xiii\).

What we do know is that immunocompromised / immunosuppressed (IC/IS) patients\(^1\) in general, and blood cancer patients in particular, have:

1. Much greater risk from COVID-19 including higher rates of hospitalization, ICU admissions and death\(^v\).
2. Higher rates of breakthrough infections after being fully vaccinated\(^v\).
3. Higher rates of their infection spreading to household contacts.
4. No simple lab test to reliably predict protection post vaccination.
5. Shown in some cases to carry and shed severe acute respiratory syndrome coronavirus 2 (or SARS-CoV-2) for months leading to the risk of introducing potentially dangerous new mutations into the broader population\(^vi\).

While \(\sim 97\%\) of the adult population has the option of a safe and extremely effective way to prevent severe COVID-19 and can re-engage in the world by getting vaccinated, the vulnerable 2-3\%, namely the IC/IS patients, continue to be cautioned by local and global health authorities not to rely on vaccines for protection\(^vii\).

\(^1\) For the purposes of this statement, we use this definition of immunocompromised: Having a weakened immune system can make you more likely to get severely ill from COVID-19. Many conditions and treatments can cause a person to be immunocompromised or have a weakened immune system. Primary immunodeficiency is caused by genetic defects that can be inherited. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html
Also, the definition of who is considered immunocompromised is unclear and absent of precise diagnostic and clinical indicators. One example is those with Chronic Lymphocytic Leukemia (CLL) who have long been recognized as being significantly immunocompromised at all stages of disease, regardless of their treatment status. Quoting from a recent study of COVID-19 vaccine response in blood cancer patients: "More than one-third (36%) of patients with CLL, the most common leukemia in U.S. adults, were seronegative after vaccination. Nearly three in ten of them had no cancer therapy in the past two years, showing that the disease itself may impair the B cell function needed to make antibodies to vaccines." Moreover, we know that we can't rely on any single blood test to determine vulnerability to COVID-19.

As a significant stressor, the COVID-19 pandemic has also resulted in the **deterioration of mental health** in some patient groups, specifically multiple stressing factors of being immunocompromised, being less protected than others, and continuation of shielding from the environment, despite the relaxation of public rules.

**Principles**

The mantra of “**Get vaccinated but act as if you are not**” is an appropriate interim solution. But we cannot expect IC/IS patients to remain locked down indefinitely as the rest of the world returns to near normal.

The special vulnerability of those with blood cancers and others needs to be addressed in a proactive way. While we need to be prepared for surprises when dealing with COVID-19, certain principles can inform best practices for the IC/IS community:

1. We recognize that there is public fatigue with health measures.
2. Public awareness of issues for IC/IS is important.
3. IC/IS blood cancer patients must be included in the priority treatment groups with those considered at high risk and most vulnerable to COVID-19 infection. **Everyone, regardless of their immune status, should be vaccinated.** The active immunity from a vaccine is preferred for those who can rely on it. The more people are vaccinated, including booster vaccine doses, the more the IC/IS are protected.
4. Strategies and actions for IC/IS need to rely on antivirals and COVID-19 monoclonal antibodies (CmAbs).
5. **Educating the IC/IS patients that continued masking and social distancing** in high-risk circumstances are essential even if the public rules on masking and social distancing are relaxed. This is especially true in settings where the IC/IS will likely be present such as during public transit and in public buildings.
6. **Safety measures and masking should continue to be maintained in any clinical setting when treating IC/IS patients** even when public rules are being relaxed.

**Recommendations**

1. **Access to fast response COVID-19 testing for high-risk patients.** Many of the lifesaving therapies must be instituted quickly after diagnosis to be effective. Waiting a week for the results of a PCR test could be a fatal delay. Possible solutions include:
   a. Special access to home tests for the IC/IS community.
   b. Testing slots set aside or special testing sites for the IC/IS.
   c. Systems should be in place at national level to process the IC/IS that test positive to COVID-19 to ensure a quick access to treatment.
2. **Access to Pre-Exposure Prophylaxis or PrEP and Post Exposure Prophylaxis or PEP, and antivirals for high-risk patients.** When vaccination doesn't provide protection, there must
be adequate access to appropriate therapies to prevent and treat infections. A critical claim, it can be achieved by accelerating the production and equitable distribution of antivirals and CmAbs. We have good options but scarce supplies.

3. **Using scientific rigor to best define who is at high risk for COVID-19.** It cannot be based on a single blood value and instead should be informed by the increasing volume of scientific literature on COVID-19 outcomes in several different IC/IS communities. This is especially true for all those with lymphoid malignancies including many lymphomas such as CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma), regardless of whether they are before, during or after treatment.

4. **More research** is needed about blood cancer and IC/IS patients and existing and future antivirals.

5. **Ensuring equitable access to best practices and treatments as well as affordable PPE and COVID-19 tests** regardless of geographic, socio-economic, racial or ethnic considerations.

6. All those who might benefit should be offered additional or “booster” vaccine doses\textsuperscript{xii}. Booster vaccine doses should be offered especially to the elderly and immunocompromised based on studies demonstrating their protective benefits.

7. **Involvement of the medical institutions in low- and middle-income countries** into the clinical studies / trials of new anti-COVID-19 medications.

8. **Provision of psychological and psycho-oncological services** specifically to the immunocompromised who need to continue shielding and social distancing despite the relaxation of public rules\textsuperscript{xiv}. Offering the right protective measures complete with a comprehensive strategy to protect the patients from the multiple stressing factors of being immunocompromised, less protected than others, being in lockdown or otherwise shielding from the environment will lead to better physical and mental health outcomes.

9. **Vaccines must be made available globally,** not only in high income countries. Reliable information about vaccines and treatments should be made available and more visible.

Until there is enough antiviral and antibody therapy for all who might benefit, difficult choices will need to be made to ensure equitable access.

Protecting the most vulnerable is not only the right thing to do, but also the smart thing to do. Protecting the immunocompromised where the virus has proven to linger and mutate, protects everyone\textsuperscript{xii}.

COVID-19 management is changing rapidly. While this represents the consensus as to best practices at the time of its publication, new options will require ongoing updates. And so, it is also essential to ramp up research into identifying the factors of neglected care for the broader patient community of IC/IS patients.

Thank you for considering the needs of this large population that has been largely forgotten during the pandemic.

---

*On behalf of the International COVID-19 Blood Cancer Coalition (ICBCC)*

21\textsuperscript{st} of February 2022
Endorsed by:

Global Patient Organisations:

Nick York, Chair
CLL Advocates Network
(Global)

Dr Brian Koffman, Executive
Vice President and Chief Medical
Officer
CLL Society
(USA)

Lorna Warwick, Chief Executive Officer
Lymphoma Coalition
(Global)

Dennis Costello, Executive
Director
CML Advocates Network
(Global)

Zack Pemberton-Whiteley, Chair
Acute Leukemia Advocates
Network, ALAN
(Global)

Hans Scheurer, President
Myeloma Patients Europe, MPE
(Europe)

Fernando Piotrowski, Executive
Director
Asociación ALMA
(Argentina)

Chris Tanti, CEO
Leukaemia Foundation
(Australia)

Sharon Winton, CEO
Lymphoma Australia
(Australia)

Hyacinth Grimes, Vice President
Lymphoma and Leukemia
Foundation of Barbados
(Barbados)

Elke Stienissen, President
Lymphoma Association Flanders
(Belgium)

Reymond Vles, Chair
CLL Canada
(Canada)
Michael Rynne, Co-founder  
CLL Ireland  
(Ireland)

Giora Sharf, Director  
Flute of Light - Home of blood cancer patients in Israel  
(Israel)

Lidija Pecova, President  
HEMA  
(Macedonia)

Mayra Galindo, Director  
Mexican Association of the Fight Against Cancer - AMLCC  
(Mexico)

Bahija Gouimi, President  
AMAL  
(Morocco)

Krishna Prasad Upadhyaya, Vice Chairman  
Blood Cancer Society Nepal  
(Nepal)

Marianne van Maarschalkerweerd, Expert Patient Advocate  
Hematon  
(The Netherlands)

Emma Barker, Head of Support Services & Operations  
Leukaemia & Blood Cancer New Zealand  
(New Zealand)

Dr Gillian Corbett, Trustee  
CLL Advocates New Zealand, CLLANZ  
(New Zealand)

Oksana Chirun, President  
Inter-regional public organization for patients with hematological diseases «Most Miloserdiya» («Mercy Bridge»)  
(Russia)

Maja Kocic, President  
Lymphoma Patient Association LYP / LIPA  
(Serbia)

Elena Palma, International Representative  
AELCLES (Spanish Network for Leukemia and Blood Disorder)  
(Spain)
Clinical community / Medical Societies:

Elizabeth Macintyre, President
European Hematology Association, EHA
(Europe)

Prof Paolo Ghia, President
European Research Initiative on CLL, ERIC
(Europe)

Prof Peter Hillmen, Chairperson
International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
(Global)

Dr Yervand Hakobyan, President
AHA - Armenian Hematology Association
(Armenia)

Vanessa O'Shaughnessy, Director Communications
Peter MacCallum Cancer Centre
(Australia)

Dr Versha Banerji, Physician
(Canada)

Prof. Alain Delmer & Prof. Pierre Feugier
CLL Scientific Board
French Innovative Leukemia Organization
(France)

Dr. Kostas Stamatopoulos, Director
Institute of Applied Biosciences
CERTH - Center for Research and Technology Hellas
(Greece)

Dr Tamar Tadmor, Physician
The Israeli CLL Study Group
(Israel)
Dr Vasile Musteata, Physician  
State University of Medicine and Pharmacy "N. Testemitanu",  
Institute of Oncology (Moldavia)

Dr Renata Walewska, Chair  
UK CLL Forum (UK)

Prof Paul Moss, Physician  
Chief Investigator of the CLL-Vaccine Response Study,  
Birmingham (UK)

Anne Crook, Counsellor / Psychotherapist, Psycho-oncology  
(UK)

Nicole Lamanna, MD  
Director CLL Program  
Hematologic Malignancies Section  
Herbert Irving Comprehensive Cancer Center  
New York-Presbyterian/Columbia University Medical Center  
(USA)

Selected References:


